Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013
2016
Abstract
To conclude, anti-TNF-α therapy in patients with moderate-to-severe HS seems more effective in a subset of patients with associated arthritis or inflammatory bowel disorders. Complete and persistent clinical response, with anti-TNF-α drugs used as a single agent, was rarely obtained.
Adalimumab seems to be more effective than infliximab and etanercept. Other therapeutic strategies, such as anti-TNF-α drugs and especially higher dosages of adalimumab used before surgery, or low-dose methotrexate in combination, have yet to be assessed.